Summary The outcome of salvage treatment was reviewed in 55 patients relapsing during or after their primary chemotherapy for advanced malignant germ cell tumours. Fifty-two patients had been given cisplatinbased chemotherapy as their primary treatment, whereas three patients had received carboplatin-based chemotherapy. The median time to relapse was 2 months (range: 0-96 months) from discontinuation of the primary treatment. Two patients underwent radical surgery only, and one patient had radiotherapy to a brain metastasis as his only curatively intended salvage treatment. Six patients did not receive any treatment for their recurrent malignancy (refusal, terminal condition) except for purely palliative measures. The disease-free survival for the total group was 27% at 5 years. Complete response to primary treatment lasting for > 6 months was the only parameter which significantly predicted a favourable outcome (45% 5 year disease-free survival in 12 eligible patients).
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Using cisplatin-based chemotherapy in the primary treatment of patients with disseminated germ cell tumours a 80-85% 5 year survival is achieved (Stoter et al., 1986; Williams et al., 1987; Aass et al., 1990; Dearnaley et al., 1991) . However, about 15% of all patients relapse after their initial treatment and need effective salvage treatment. The overall 5 years survival in these patients has been reported to be between 20 to 30% with no clear advantage of any salvage regimen (Motzer et al., 1991; Harstrick et al., 1991) .
In the present retrospective study we review the results of salvage treatment in patients with malignant germ cell tumours who have been treated at the Norwegian Radium Hospital (NRH) for relapse after the primary treatment with cisplatin or carboplatin-based combination chemotherapy. Particular emphasis is put on identification of prognostic factors which are correlated with favourable long term survival. (Longo et al., 1991) .
Patients and methods

Patients
Twenty-nine patients underwent post-chemotherapy surgery, most often retroperitoneal lymph node dissection (RLND). Four patients in whom vital malignant germ cell cancer was found in the post-chemotherapy histological section received three adjuvant chemotherapy cycles post-operatively. Most patients received between two and four cycles of chemotherapy depending on development of the disease and toxicity. Fourteen patients underwent surgery as part of their salvage treatment (RLND: six, Thoracotomy: seven, Other: one). Fourteen patients had radiotherapy, most often given with palliative intention.
Follow-up As a rule patients underwent bi-monthly clinical, radiological and biochemical examinations during the first year after discontinuation of their treatment, later on with increasing intervals. All patients were followed until death or until May 1st 1992 (medial observation time from start of salvage treatment for surviving patients: 48 months; range 2-119 months).
Statistics
All calculations were made by the PC based 'Medlog' program, applying common statistical procedures (Median, Fisher exact probability test, Kaplan Meier survival analysis, Logrank test). A P-value <0.05 was regarded as statistically significant.
Results
In 23 patients the re-activation of the malignancy presented as increase of serum alpha-foetoprotein (AFP) and/or of human choriogonadotropin (HCG). 
Survival
At the end of the observation time 17 patients are alive without evidence of disease. Three additional patients are alive with progressing germ cell malignancy. The 5 year disease-free survival for all relapsing patients was 27% (Figure la ). Most patients with disease reactivation after salvage chemotherapy died within the first 2 years after their relapse, though 2 patients survived for more than 3 years. Achievement of a CR1 during primary treatment and a relapse-free interval of > 6 months were associated with a favourable disease-free survival (P: 0.097 and 0.051, respectively) (Table IV) . The combination of these two parameters was associated with a 38% 5 year disease-free survival ( Figure lb) Myelo-suppression was the most frequent toxicity during salvage treatment, requiring dose reductions or delay of scheduled chemotherapy. Nephrotoxicity (WHO grade > 2) led to dose modifications of salvage treatment in four patients. One patients who had relapsed with liver metastases, died of neutropenic septicaemia after the second carboplatin-Etoposide cycle. At autopsy no metastases were found.
Discussion
During salvage chemotherapy objective responses (significant tumour marker decrease, > 50% reduction of tumour masses) were observed in the majority of patients, though these remissions were often short-lasting. The overall disease-free survival in our patients with malignant germ cell tumours relapsing after initial cisplatin-or carboplatin-based chemotherapy was thus only 27%, which is comparable to reported observations from other groups (Motzer et al., 1991; Harstrick et al., 1991) . The results of third line treatment are even more dismal. In our opinion therapeutic trials after failure of second line treatment should only be performed if the oncologist and the patient have thoroughly considered all cost-benefit aspects of such third line chemotherapy.
In our series only complete response after primary treatment (without residual vital malignant germ cell tumour) lasting for at least 6 months correlated with long-term survival after salvage chemotherapy. Patients fulfilling these criteria, most probably have chemotherapy-sensitive tumours and re-induction with intensive cisplatin-based chemotherapy may be successful.
In the present series initial tumour burden did surprisingly not have any influence on survival, contrary to observations from the Royal Marsden Hospital (Gildersleve et al., 1991 (Motzer et al., 1990; Horwich et al., 1991) . It is too early to decide what percentage of patients relapsing after carboplatin treatment can be salvaged by secondary cisplatinbased chemotherapy. Of our three patients relapsing after initial carboplatin-based treatment a complete durable response was achieved in only one patient (lasting for 27 + months).
One of five patients (Table IV (Spears et al., 1991) . Surgery may in selected cases be of critical significance for the cure of patients resistant to salvage chemotherapy (Cassidy et al., 1992) .
In addition, surgery has an important diagnostic role in patients with increasing tumour manifestations after their initial cisplatin-based chemotherapy, in particular, if regrowth of a lesion is diagnosed many months after the primary treatment in a patient with normal levels of HCG and AFP. In such cases histology often will reveal mature teratoma or even completely necrotic tumour tissue, as in one of our patients relapsing after 8 years. The growing teratoma syndrome after chemotherapy has been described by several authors (Basheda et al., 1991 , Jansen et al., 1991 and represents a condition which has to be treated surgically. Late re-growth of residual completely necrotic metastasis has not been reported previously.
In our series the development of nephrotoxicity was not a major clinical problem during salvage chemotherapy and did only rarely lead to dose reduction of the cytostatic agent or treatment delay. Myelotoxicity, on the other hand, led to frequent dose reductions and treatment delays. During the last year hematopoetic growth factors were applied in three patients to avoid such dose modifications and to enable the application of sufficient doses at short intervals. Other groups have considered autologous bone marrow transplantation (Eder et al., 1990; Broun et al., 1991; Droz et al., 1991) to overcome myelotoxicity during high dose salvage chemotherapy. However, so far no observations are available proving that high or ultra high-dosed salvage chemotherapy improves survival rates after salvage chemotherapy, in particular, when unselected patients are considered.
In conclusion, only about 25% of testicular cancer patients relapsing after initial cisplatin-based chemotherapy survive without evidence of disease for 3 years or more. These overall disappointing results should be kept in mind when the decision is made whether to treat an individual relapsing patient or not, especially if the patient himself is reluctant to further chemotherapy. CR to initial chemotherapy lasting for at least 6 months is correlated with a favourable long-term outcome. Radiotherapy and/or surgery are worthwhile additive treatment modalities and can in a few patients be critical for the achievement of disease-free survivorship. Myelotoxicity correlated with the risk of serious infections represented the most frequent and most severe complication during salvage treatment.
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